---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-032296"
form_type: "8-K"
ticker: "AVR"
cik: "0002011514"
company_name: "Anteris Technologies Global Corp."
filed_at: "2026-08-11T23:07:30+00:00"
generated_at: "2026-08-12T10:05:39.725951+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Anteris six-month 2026: revenue $1.503M (+28% YoY), net loss widens to $52.1M

## Summary
- Six-month revenue $1.503M vs $1.174M prior year; loss attributable to members $52.118M vs $42.698M (22% worse).
- Q2 2026 net operating cash outflows $20.8M; R&D expenses $23.4M driven by PARADIGM trial scaling and manufacturing.
- CMS granted Medicare reimbursement for PARADIGM trial procedures under TAVR NCD 20.32; U.S. enrollment began May 2026.
- Trial active in U.S., Denmark, Netherlands; regulatory clearance secured in Canada and France; ~1,000-patient randomized study.
- No dividend proposed; board appointments of Susan Knight and Stephen Denaro during the quarter.

## SEC filing metadata
- accession: 0001140361-26-032296
- form_type: 8-K
- ticker: AVR
- cik: 0002011514
- company_name: Anteris Technologies Global Corp.
- filed_at: 2026-08-11T23:07:30+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2011514/000114036126032296/0001140361-26-032296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2011514/000114036126032296/ef20079835_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-032296
- JSON: https://secwatch.observer/filing/0001140361-26-032296.json
- Plain text: https://secwatch.observer/filing/0001140361-26-032296.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.